Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ranbaxy Board Approves Spin-off Of Drug Discovery Company

This article was originally published in PharmAsia News

Executive Summary

Ranbaxy Laboratories is moving to "de-merge" its drug discovery activities into a separate company with dedicated resources, the firm announced Oct. 18
Advertisement

Related Content

Ranbaxy Delays Spin Off Of R&D Unit Until Later This Year
Ranbaxy Delays Spin Off Of R&D Unit Until Later This Year
Nicholas Piramal India Inks R&D Deal With Merck
Nicholas Piramal India Inks R&D Deal With Merck
Ranbaxy Augments Dermatology Line With U.S. Purchase Of Brands From Bristol-Myers Squibb
Ranbaxy/GSK Partnership Yields First Drug Candidate
Advertisement
UsernamePublicRestriction

Register

SC065716

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel